A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

Part of paid clinical trials in Secaucus, New Jersey.

Sponsor
Shanghai World Leader Pharmaceutical Co., Ltd.
Study ID
NCT07465965
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.

Key Dates

Start date
Mar 2, 2026
Status verified
Mar 2026
Primary completion
Aug 21, 2026
Completion
Aug 30, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A0 : Semaglutide Nasal Spray
  • Experimental: Cohort A1: Semaglutide nasal spray and placebo
  • Experimental: Cohort A2:Semaglutide nasal spray and placebo
  • Active Comparator: Cohort A3: Semaglutide injection

Primary Outcome Measure

Maximum Plasma Concentration (Cmax) [ Time Frame: Day 1 to Day 36 after administration ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Frontage Clinical Services, Inc.SecaucusNew Jersey07094
12014167766

Find similar trials in Secaucus, NJ

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Frontage Clinical Services, Inc.· Secaucus, NJ

Related Studies